Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Xetra  >  Bayer AG    BAYN   DE000BAY0017


News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Animal health sector aims to emulate Zoetis biotech leap

share with twitter share with LinkedIn share with facebook
share via e-mail
09/19/2019 | 02:56pm EDT

(Reuters) - A commercial breakthrough in the field of complex therapeutic proteins for dogs by sector leader Zoetis has roused rivals to action in a hunt for biotechnology medicines to treat pets.

Previously reserved for humans, biotech drugs made from genetically engineered living cells are now seen as ripe for the pet health market. The following are some of the recent deals, launches and development projects in the space:

- British animal health company Dechra Pharmaceuticals Inc agreed to a deal https://www.akstonbio.com in August to utilize development work by U.S. insulin specialist Akston Biosciences for a once weekly shot for diabetic dogs to replace daily injections, with a view to expanding the collaboration to cats. Dechra has said long-acting insulin, which is typically produced from genetically modified bacteria, should become its biggest product.

- U.S. animal health company Kindred Biosciences Inc, which repurposed a human antidepressant to stimulate appetite in underweight cats, has several genetically engineered biologic drugs under development https://kindredbio.com/pipeline, targeting diseases such as dermatitis in dogs and anemia in cats.

- German early-stage biotech research firm Adivo in April signed a global collaboration deal https://media.bayer.com/baynews/baynews.nsf/id/Bayer-Animal-Health-and-adivo-sign-global-collaboration-agreement with Bayer's animal health unit a little over a year after Adivo was spun out of human biotech firm Morphosys with a mission to develop antibodies for dogs.

- Privately-held German drugmaker Boehringer Ingelheim, the global No. 2 in animal health, in April launched https://www.boehringer-ingelheim.com/press-release/arti-cell-forte-stem-cell-based-veterinary-product the first stem cell-based veterinary medicine to treat lameness in horses caused by inflamed joints, a common worry for both recreational and competitive riders.

- Industry leader Zoetis Inc, which has a successful anti-itch biotech drug for dogs on the market, said https://investor.zoetis.com/sites/zoetis.investorhq.businesswire.com/files/doc_library/file/ZTS_Q2_2019_Corrected_Transcript.pdf in August it was seeking approval for more antibodies, targeting osteoarthritic pain in cats with plans for a 2021 market launch, drawing on its 2017 acquisition of Nexvet Biopharma. A similar product for dogs is also in the pipeline.

- In June of 2018, Zoetis signed a deal https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-zoetis-announce-collaboration-research-antibody with human biotech firm Regeneron Pharmaceuticals Inc to adopt its antibody technology for animals, targeting inflammatory disease and cancer.

(Reporting by Ludwig Burger; Edited by Bill Berkrot)

By Ludwig Burger

Stocks mentioned in the article
ChangeLast1st jan.
BAYER AG 2.31% 66.5 Delayed Quote.7.33%
DECHRA PHARMACEUTICALS 0.55% 2558 Delayed Quote.22.90%
KINDRED BIOSCIENCES, INC. -0.13% 7.91 Delayed Quote.-27.67%
MORPHOSYS -1.92% 102.2 Delayed Quote.17.14%
REGENERON PHARMACEUTICALS 1.23% 305.02 Delayed Quote.-19.33%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on BAYER AG
07:15aBAYER AKTIENGESELLSCHAFT : Release according to Article 40, Section 1 of the WpH..
10/22BAYER : EU to ban Bayer's pesticide linked to harming bees
10/22BAYER : 'Biologicals by Bayer', leading innovation for organic crop protection s..
10/21Temasek makes $3 billion bid for Singapore's Keppel, sparks sector M&A talk
10/21BAYER : Seeks FDA OK to Extend Mirena Duration to Six Years
10/21Roche pushes late-comer Tecentriq as new liver cancer option
10/21BAYER : “Biologicals by Bayer”, leading innovation for organic crop ..
10/17BAYER AKTIENGESELLSCHAFT : Release according to Article 40, Section 1 of the WpH..
10/16Factbox - How are businesses preparing for a 'no-deal Brexit'?
10/16ATOS : Signs Contract With Bayer for Digital Workplace Services
More news
Financials (EUR)
Sales 2019 45 818 M
EBIT 2019 8 205 M
Net income 2019 3 161 M
Debt 2019 37 519 M
Yield 2019 4,28%
P/E ratio 2019 21,0x
P/E ratio 2020 13,7x
EV / Sales2019 2,17x
EV / Sales2020 2,04x
Capitalization 62 015 M
Duration : Period :
Bayer AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BAYER AG
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 79,41  €
Last Close Price 66,50  €
Spread / Highest target 85,0%
Spread / Average Target 19,4%
Spread / Lowest Target -41,7%
EPS Revisions
Werner Baumann Chairman-Management Board
Werner Wenning Chairman-Supervisory Board
Wolfgang U. Nickl Chief Financial Officer
Katharina Jansen Head-Science & Research
Hartmut Klusik Head-Human Resources, Technology & Sustainability
Sector and Competitors
1st jan.Capitalization (M$)
BAYER AG7.33%67 531
JOHNSON & JOHNSON0.12%340 980
ROCHE HOLDING AG18.71%249 928
PFIZER-16.54%201 496
NOVARTIS15.69%199 249